Roche has reported positive prespecified interim Phase III results for sefaxersen in primary IgA nephropathy, with the investigational once-monthly therapy significantly reducing proteinuria compared with placebo after 37 weeks. The IMAgINATION study met its primary endpoint using 24-hour urine protein-to-creatinine ratio, a measure with direct regulatory relevance because reduction in proteinuria has already supported accelerated approvals for several IgA nephropathy therapies in the United States. Roche plans to present the detailed interim results at an upcoming medical meeting and share the findings with health authorities, potentially moving sefaxersen closer to regulatory discussions while the trial continues to evaluate longer-term kidney function.
The result adds another serious competitor to a rapidly changing IgA nephropathy market in which Novartis and other drugmakers have already secured approvals using several different biological mechanisms. Roche described the proteinuria reduction as clinically meaningful and said no new safety signals emerged, although it has not yet disclosed the percentage reduction, confidence intervals or detailed adverse-event rates. Those missing numbers will be essential before sefaxersen can be meaningfully compared with established therapies or other late-stage programs.
IMAgINATION Phase III interim analysis gives Roche an important efficacy signal at 37 weeks
IMAgINATION is a randomized, double-blind, placebo-controlled Phase III trial enrolling 459 adults with primary IgA nephropathy who are considered at high risk of disease progression. Participants were randomized one-to-one to receive sefaxersen or placebo for 105 weeks, with proteinuria reduction at week 37 serving as the primary endpoint.
The study met that endpoint at the prespecified interim analysis, with sefaxersen producing a statistically significant improvement in 24-hour urine protein-to-creatinine ratio compared with placebo. Roche has not yet released the precise treatment difference, meaning the strength of the result beyond statistical significance remains difficult to judge from the topline announcement alone.
That limitation matters because the IgA nephropathy treatment landscape has become considerably more competitive. Novartis’ Vanrafia previously received accelerated FDA approval after reducing proteinuria by 36.1% versus placebo at week 36, while Fabhalta has since obtained traditional approval after demonstrating a 49.3% slowing of kidney-function decline over two years. Any claim that sefaxersen may eventually offer best-in-class efficacy therefore requires the full numerical IMAgINATION dataset rather than comparisons based on Roche’s topline description.
The study is not ending with the interim proteinuria analysis. Participants will remain blinded through week 105 so investigators can determine whether sefaxersen slows deterioration in estimated glomerular filtration rate, or eGFR, a more direct measure of kidney function. That longer-term result could ultimately be more important clinically because the central objective in IgA nephropathy is delaying progression toward kidney failure, dialysis or transplantation.
Sefaxersen targets complement factor B through a once-monthly antisense approach
Sefaxersen uses an antisense oligonucleotide designed to reduce production of complement factor B in the liver, where much of the circulating protein is produced. Factor B is a central component of the alternative complement pathway, which can become abnormally activated in IgA nephropathy and contribute to inflammation and kidney damage.
Rather than directly blocking circulating factor B with an antibody or small molecule, sefaxersen acts at the messenger RNA level to reduce production of the protein. Roche describes it as the first mRNA-targeted therapy being developed for IgA nephropathy. The drug is administered through a subcutaneous injection once every month and is intended to support self-administration.
That dosing profile could become commercially relevant if efficacy and safety remain competitive. IgA nephropathy is a chronic disease commonly diagnosed before age 40, meaning patients may require long periods of treatment. A once-monthly self-administered regimen could reduce dosing burden compared with weekly injectable therapies, although oral drugs would retain a convenience advantage for many patients.
Roche licensed sefaxersen from Ionis Pharmaceuticals after positive Phase II results. Ionis disclosed that Roche assumed responsibility for global development, regulatory activities and commercialization after exercising its license in 2022. Under the agreement, Ionis remains eligible for development, regulatory and sales milestones totaling as much as $430 million, along with tiered royalties ranging from the high teens to approximately 20% of net sales.
IgA nephropathy competition is intensifying as multiple mechanisms reach the market
The opportunity facing Roche is substantial but increasingly crowded. IgA nephropathy is a progressive autoimmune kidney disease in which abnormal immune complexes accumulate in the kidneys and activate inflammatory pathways. Roche said as many as half of affected patients can progress to kidney failure within 20 years of diagnosis.
Treatment options have expanded rapidly. Novartis now markets Fabhalta, which directly inhibits complement factor B, and Vanrafia, an endothelin type A receptor antagonist. Fabhalta received traditional FDA approval in July after showing a significant reduction in the rate of kidney-function decline, raising the clinical benchmark for future therapies that also target the alternative complement pathway.
Other mechanisms are also entering the field. The FDA granted accelerated approval to Otsuka Pharmaceutical’s Voyxact to reduce proteinuria, while Vera Therapeutics’ Trutakna received approval in 2026 as the first therapy targeting both BAFF and APRIL. That increasingly diverse competitive environment means sefaxersen will likely need a strong combination of efficacy, safety, dosing convenience and durable preservation of kidney function rather than proteinuria reduction alone.
Roche’s eventual commercial positioning could depend heavily on the week-105 eGFR result. If the proteinuria benefit translates into meaningful preservation of kidney function, sefaxersen could become another disease-modifying option in a market where physicians increasingly have the ability to target several components of IgA nephropathy biology.
Phase III success strengthens Roche’s immunology pipeline as investors await the full data
The sefaxersen result arrives while Roche is generating broader pipeline momentum. Group sales rose 6% at constant exchange rates during the first half of 2026 to CHF 30.36 billion, with pharmaceutical sales also increasing 6% at constant currencies. Roche has reaffirmed its expectation for mid-single-digit full-year sales growth and high-single-digit growth in core earnings per share.
Sefaxersen could add another asset to a growing autoimmune and kidney-disease portfolio if regulators ultimately accept the program. The Phase III result also validates part of Roche’s collaboration strategy with Ionis Pharmaceuticals by taking a licensed antisense therapy through a successful pivotal interim analysis.
The stock reaction has been relatively subdued compared with the clinical importance of the announcement. Roche’s United States-traded ADRs were around $55.15 during September 23 trading, down roughly 0.9% intraday, while Roche securities in Switzerland remained near the upper portion of their 52-week range. The muted move suggests investors view sefaxersen as one contributor within a much larger pharmaceutical pipeline rather than a single asset capable of materially changing Roche’s near-term financial profile. The upcoming detailed presentation should provide a much clearer basis for evaluating that opportunity. Investors and nephrologists will be looking for the exact placebo-adjusted proteinuria reduction, consistency across patient subgroups, complement factor B suppression, adverse events and whether treatment benefits were evident alongside contemporary background therapies.
For now, Roche has achieved the result needed to keep sefaxersen moving toward regulators. The more important long-term test remains whether lowering factor B and proteinuria once monthly can ultimately preserve kidney function strongly enough to compete in an IgA nephropathy market that is advancing faster than almost any other area of nephrology.
